Kestra Medical Technologies (NASDAQ:KMTS) Insider Timothy Moran Sells 2,380 Shares of Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Timothy Moran sold 2,380 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $23.76, for a total transaction of $56,548.80. Following the sale, the insider directly owned 66,345 shares of the company’s stock, valued at approximately $1,576,357.20. The trade was a 3.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Trading Up 5.1%

NASDAQ:KMTS opened at $23.99 on Tuesday. Kestra Medical Technologies, Ltd. has a one year low of $14.10 and a one year high of $30.00. The business has a fifty day moving average price of $22.62 and a 200-day moving average price of $22.48. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -9.91 and a beta of 0.58. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. Sell-side analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. BTIG Research increased their price objective on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. The Goldman Sachs Group lowered their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Oppenheimer began coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating for the company. Finally, Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Kestra Medical Technologies presently has an average rating of “Hold” and a consensus target price of $27.83.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Seven Grand Managers LLC bought a new stake in shares of Kestra Medical Technologies during the fourth quarter valued at approximately $2,652,000. Eventide Asset Management LLC boosted its position in shares of Kestra Medical Technologies by 5.4% during the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after acquiring an additional 65,288 shares during the last quarter. Summit Partners Public Asset Management LLC purchased a new position in Kestra Medical Technologies during the fourth quarter valued at $9,282,000. UBS Group AG increased its holdings in Kestra Medical Technologies by 34.9% in the 4th quarter. UBS Group AG now owns 270,058 shares of the company’s stock valued at $7,162,000 after acquiring an additional 69,908 shares during the last quarter. Finally, Jennison Associates LLC lifted its stake in Kestra Medical Technologies by 15.0% in the 4th quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock worth $5,817,000 after purchasing an additional 28,573 shares in the last quarter.

Key Stories Impacting Kestra Medical Technologies

Here are the key news stories impacting Kestra Medical Technologies this week:

• Neutral Sentiment: Multiple executives, including CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran, sold shares between July 30 and August 3. The transactions totaled approximately 103,000 shares and more than $2.3 million at prices near $22.60–$23.92. Each filing states that the sales were made to cover tax-withholding obligations tied to vested equity awards, rather than for discretionary investment purposes. SEC insider transaction filings
• Negative Sentiment: The breadth of the selling—including transactions by the CFO and several other insiders—could weigh on sentiment because it reduces management ownership and creates a perception of insider selling pressure. However, the relatively small percentage reductions in most positions and the disclosed tax-related purpose make the signal less bearish than open-market sales based on an expectation of weaker business performance.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.